Results Briefing Presentation Q1 2017 2017... · 5 Q1 2017 Highlights Resilient core financial performance o Revenue increased 8% to RM2.7bil, o EBITDA decreased 8% to RM565.4mil

© All Rights Reserved.

This material is confidential and property to IHH Healthcare Berhad. No part of this material

should be reproduced or published in any form by any means, nor should the material be

disclosed to third parties without the consent of IHH.

Results Briefing Presentation

Q1 2017

19 May 2017

2

Disclaimer

This document is and shall remain the exclusive property of IHH Healthcare Berhad (the “Company”) and nothing herein shall give, or shall be construed

as giving, to any party any right, title, ownership, interest, licence or any other right whatsoever in or to this document. Neither this document nor any part

thereof may be (i) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (ii) redistributed, passed on or otherwise

disseminated, without the Company’s permission.

Although care has been taken to ensure that the information in this document is accurate, and that the opinions expressed are fair and reasonable, the

information is subject to change without notice, its accuracy is not guaranteed, has not been independently verified and it may not contain all material

information concerning the Company and its subsidiaries and associate companies. None of the Company nor its subsidiaries or associate companies nor

any of its or their respective members, directors, officers, employees, affiliates or advisors make any representation or warranty (express or implied)

regarding, nor assumes any responsibility or liability for, the accuracy, reasonableness, fairness or completeness of, or any errors or omissions in, any

information contained herein. Accordingly, none of the above nor any other person accepts any liability (in negligence, or otherwise) for any loss arising

from or in connection with any use of this document or its contents.

This document is for information purposes only and does not constitute or form part of any offer or invitation by or on behalf of the Company for sale or

subscription of or solicitation or invitation of any offer to or recommendation to buy or subscribe for any securities (“Securities”), nor shall it or any part of it

form the basis of or be relied on in connection with any contract, commitment or investment decision in relation to the Securities of the Company in

Malaysia, Singapore or any other jurisdiction. The information in this document does not take into consideration the investment objectives, financial

situation or particular needs of any particular investor, and should not be treated as giving investment advice.

In addition, this document contains certain financial information and results of operation, and may also contain certain projections, plans, strategies, and

objectives of the Company, that are not statements of historical fact which would be treated as forward looking statements that reflect the Company’s

current views with respect to future events and financial performance. These views are based on a number of estimates and current assumptions which are

subject to business, economic, political and competitive uncertainties and contingencies as well as various risks which are in many cases outside the

control of the Company, and which may change over time and may cause actual events and the Company’s future results to be materially different than

expected or indicated by such statements. No assurance can be given that future events will occur, that projections will be achieved, or that the Company’s

assumptions are correct. Such forward‐looking statements are not guarantees of future performance and accordingly, the actual results, financial condition,

performance or achievements of the Company may differ materially from those anticipated by the Company in the forward looking statements. You are

cautioned not to place undue reliance on these forward looking statements.

The Company does not undertake to provide you with access to any additional information or to update the information contained in the document or to

correct any inaccuracies therein which may become apparent.

3

Agenda

Q1 2017 Group Key Highlights

Key Operational Highlights

o Inpatient admissions and revenue intensity

o Project progress – 2017

o Project progress – 2018 & beyond

Key Financial Highlights

o Key Group Highlights (without PLife REIT results)

o Performance by SBUs (in key metrics)

o Balance sheet and cashflows

o Expansion capital expenditure

Outlook and Prospects

4

Strong results from existing operations

EBITDA and PATMI (Excl EI) eroded by New Hospitals

Total Group Results

RM'mil

Revenue

EBITDA

EBITDA Margin (%)

PATMI

PATMI Margin (%)

PATMI

(Excluding exceptional items)

PATMI Margin (%)


2017 2016 Variance

2,684.8 2,475.4 8%

565.6 617.0 -8%

21.1% 24.9% -3.9%

470.0 235.5 100%

17.5% 9.5% 8.0%

201.8 238.3 -15%

7.5% 9.6% -2.1%

YTD Mar

5

Q1 2017 Highlights

Resilient core financial performanceo Revenue increased 8% to RM2.7bil,

o EBITDA decreased 8% to RM565.4mil

o PATMI (Excl EI*) decreased 15% to RM201.8mil

o EBITDA and PATMI (Excl EI) eroded by pre-operating and start-up costs of Gleneagles Hong Kong

Hospital and Acibadem Altunizade Hospital, both opened in March 2017

Sustained expansion and excellence in operationso Growth in inpatient admissions and revenue intensity across all home markets

Rebalancing portfolio, with focus on core operations Divested divestment of non-core 6.07% interest in Apollo Hospitals for RM313.4 million gain

Maintained strong financial position and balance sheeto Gearing of 0.20 times at March 2017

o Cash position of RM2.8 billion

Note*: excludes exceptional items





6

Key Operational Highlights

7

Growth in patient volumes and revenue intensities across home markets

Inpatient Admission Volumes1 (Number)

Q42015

Q12016

Q42016

Q12017

45,675

49,026 47,318

50,541

PPL - Malaysia

Q42015

Q12016

Q42016

Q12017

17,335

18,094 18,174

18,842

PPL - MalaysiaPPL - Singapore

Q42015

Q12016

Q42016

Q12017

34,372

39,296

50,470

52,581

PPL - MalaysiaAcibadem

Q42015

Q12016

Q42016

Q12017

14,712

14,033

15,838 16,008

PPL - MalaysiaPPL - India

Average Revenue per Inpatient Admission1 (RM)

Q42015

Q12016

Q42016

Q12017

27,763

28,819 28,697

29,666

PPL - MalaysiaPPL - Singapore2,3

Q42015

Q12016

Q42016

Q12017

5,475

5,583

6,151 6,185

PPL - MalaysiaPPL - Malaysia2

Q42015

Q12016

Q42016

Q12017

9,595

8,977

8,521

9,340

PPL - MalaysiaAcibadem2,3

Q42015

Q12016

Q42016

Q12017

6,924

8,006 8,110

8,255

PPL - MalaysiaPPL - India2,3

The above charts are not drawn to scale.

1. Based on Singapore, Malaysia, India and Acibadem Holdings hospitals only. Excludes hospitals operated by joint venture companies, hospitals under hospital management agreements and

other international hospitals.

2. Specialist fees not included in Singapore’s and Malaysia’s average revenue per inpatient admission

3. Based on a uniform exchange rate throughout the periods shown (SGD: 3.1626; INR:0.0677; TL:1.2263)

Q1 YoY Growth 4.1% Q1 YoY Growth 3.1% Q1 YoY Growth 14.1% Q1 YoY Growth 33.8%

Q1 YoY Growth 2.9% Q1 YoY Growth 10.8% Q1 YoY Growth 3.1% Q1 YoY Growth 4.0%

8

Project Progress 2017

Country Type Hospital Description Target Completion

Malaysia ExpansionPantai Hospital

Kuala Lumpur

Phase 2:

~120 beds capacity• Late 2017

Malaysia GreenfieldGleneagles MediniHospital

Phase 1b:

Medical Office Block

160 Medical Clinic Suites

• Late 2017

9

Project Progress 2018 and beyond


Turkey Expansion Acibadem Maslak 210 bed capacity • 2018

China Greenfield Gleneagles Chengdu 350 bed capacity • 2018

China Greenfield Gleneagles Nanjing 70 bed capacity • 2019

Turkey GreenfieldAcibadem Kartal,

Istanbul120 bed capacity • 2019

Turkey GreenfieldAcibadem Atasehir,

Istanbul180 bed capacity • 2019

10

Project Progress 2018 and beyond


Malaysia ExpansionPantai Hospital Ayer

Keroh160 beds capacity • 2019

China Greenfield Gleneagles Shanghai 450 beds capacity • 2020

Malaysia Expansion Pantai Hospital Klang 80 beds capacity • Planning stage





11

Key Financial Highlights

12

Double-digit Revenue growth on constant currency

EBITDA and PATMI (Excl EI) eroded by New Hospitals

Excluding PLife REIT’s Results

RM'mil

Revenue

EBITDA

EBITDA Margin (%)

PATMI

PATMI Margin (%)

PATMI


PATMI Margin (%)


2017 2016 Variance

Variance

(@ Constant

Currency)

2,652.3 2,444.4 9% 13%

496.6 551.9 -10% -7%

18.7% 22.6% -3.9% -3.9%

452.5 221.0 105% 94%

17.1% 9.0% 8.0% 6.5%

184.2 223.8 -18% -17%

6.9% 9.2% -2.2% -2.4%

YTD Mar

13

Key Financial Highlights(Excluding Plife REIT’s results)

Q1 2017 Revenue grew 9%; EBITDA declined 10%; PATMI (Excl EI) declined 18%

Robust revenue performance mainly driven by:

o Healthy inpatient admissions numbers and revenue intensity

o Contribution from the ramp up of hospitals opened in 2015

o Contribution from Gleneagles Hong Kong Hospital and Acibadem Altunizade Hospital, both opened in

March 2017

o Contribution from Tokuda and City Clinic Groups in Bulgaria, which were acquired in June 2016

EBITDA eroded by:

o Pre-operating and start-up losses for Gleneagles Hong Kong Hospital and Acibadem Altunizade

Hospital

PATMI (Excl EI) declined mainly due to:

o Incremental depreciation, amortisation and finance costs with the opening of Gleneagles Hong Kong

Hospital and Acibadem Altunizade Hospital

Stronger Singapore Dollar (“S$”) partially offset by weaker Turkish Lira (“TL”) in Q1 2017 on

translation of subsidiary groups’ income statements*

*: Movements in key average exchange rates used to translate the results of significant overseas subsidiaries into RM:

SGD Average Rates Variance YTD

vs Last Year 4.8%

TL Average Rates Variance YTD

vs Last Year -15.6%

14

Exceptional Items

RM'mil 2017 2016 Variance

Profit after tax and minority interests 470.0 235.5 100%

Add back/(Less): Exceptional Items

Gain on dispoal of quoted available-for-sale financial instrumentsi

(313.4) -

Exchange loss/(gain) on net borrowingsii

94.1 5.8

(219.4) 5.8

Add/(less): Tax effects on exceptional items (18.8) (1.2)

(238.2) 4.7

Add/(less): Minority interest share of exceptional items (30.1) (1.9)

(268.3) 2.8

Profit after tax and minority interests

(Excluding exceptional itemsiii

) 201.8 238.3 -15%

Less: PATMI contribution from PLife REIT (17.5) (14.5)

Profit after tax and minority interests

(Excluding exceptional itemsiii

and PLife REIT) 184.2 223.8 -18%

YTD Mar

Note:

i) Gain on disposal of 6.07%% interest in Apollo Hospital Enterprise Limited

ii) Exchange differences arising from foreign currency denominated borrowings/payables net of foreign currency denominated cash/receivables

(As at 31 Mar 2017, Euro/TL = 3.9083; USD/TL = 3.6386)

iii) Exceptional items, net of tax and non-controlling interests

15

Contribution across the Group

RM'mil

PPL-Singapore

PPL-Malaysia

PPL-China

PPL-HK

PPL-India

PPL-Others

Acibadem Holdings

IMU Health

REIT

Others

Check to highlights

Others, 0%

REIT, 6%

IMU Health, 6%

Acibadem Holdings, 10%

PPL-Others, 3%

PPL-India, -7%

PPL-HK, -7%

PPL-China, 4%

PPL-Malaysia, 22%

PPL-Singapore, 63%

-20% 0% 20% 40% 60% 80%

Others, 0%

REIT, 1%

IMU Health, 2%


PPL-Others, 2%

PPL-India, 6%

PPL-HK, 0%

PPL-China, 2%

PPL-Malaysia, 16%

PPL-Singapore, 36%

0% 10% 20% 30% 40%

Others, 0%

REIT, 1%

IMU Health, 2%


PPL-Others, 2%

PPL-India, 5%

PPL-HK, 0%

PPL-China, 2%

PPL-Malaysia, 16%

PPL-Singapore, 37%

0% 10% 20% 30% 40%

Others, 0%

REIT, 11%

IMU Health, 4%


PPL-Others, 3%

PPL-India, 0%

PPL-HK, -1%

PPL-China, 3%

PPL-Malaysia, 17%

PPL-Singapore, 39%

-10% 0% 10% 20% 30% 40% 50%

Others, -2%

REIT, 12%

IMU Health, 5%


PPL-Others, 2%

PPL-India, 0%

PPL-HK, -15%

PPL-China, 2%

PPL-Malaysia, 23%

PPL-Singapore, 47%

-20% -10% 0% 10% 20% 30% 40% 50% 60%

Others, -4%

REIT, 9%

IMU Health, 9%


PPL-Others, -1%

PPL-India, -7%

PPL-HK, -36%

PPL-China, 4%

PPL-Malaysia, 34%

PPL-Singapore, 82%

-60% -40% -20% 0% 20% 40% 60% 80% 100%

YTD 2017 PATMI (Excl EI)

YTD 2016 PATMI (Excl EI)

YTD 2017 Revenue YTD 2017 EBITDA

YTD 2016 Revenue YTD 2016 EBITDA

16

Revenue: Robust YoY & QoQ growth from existing operations

Revenue (RM ‘mil) Variances

“Others” segment comprises of IHH Group corporate offices as well as other

investment holding entities

“New Hospitals” as referred to in these slides refers to:

Parkway Pantai – Malaysia

- Gleneagles Kota Kinabalu (Opened in May 2015)

- Gleneagles Medini (Opened in Nov 2015)

Parkway Pantai – North Asia

- Gleneagles Hong Kong Hospital (Opened in Mar 2017)

- Gleneagles Shanghai Hospital

- Gleneagles Chengdu Hospital

- Gleneagles Nanjing Hospital

Acibadem Holdings – Turkey

- Acibadem Taksim Hospital (Opened in Oct 2015)

- Acibadem Altunizade Hospital (Opened in Mar 2017)

1,533.7 1,493.5 1,525.8 1,549.41,649.1

- - -

10.213.2

17.3 21.8

25.0

- - -

819.0 853.2 795.0

945.6887.8

- - -

17.0 14.6 13.7

22.127.0

- - -

58.2 65.9 55.0

58.062.9

- - -

30.9 32.3 34.4

34.032.5

-- -

48.8 48.0 49.3

50.351.7

- - -

2,475.4 2,473.3 2,441.8

2,631.52,684.8

- - -

Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017

Segments

GROUP 2% 8% 8%

GROUP (Excl REIT) 2% 9% 9%

PLife REIT (External) -4% 5% 5%

Others -16% -92% -92%

IMU Health 9% 8% 8%

Acibadem Holdings (New) 22% 59% 59%

Acibadem Holdings (Existing) -6% 8% 8%

Parkway Pantai (New) 15% 144% 144%

Parkway Pantai (Existing) 6% 8% 8%

PLife REIT Interco Revenue

Q1'17

vs Q4'16

Q1'17

vs Q1'16

YTD'17

vs YTD'16

17

Revenue: Actual Q1 revenues eroded by the depreciation of TL;

Mitigated by the appreciation of S$

Revenue Variance (RM’mil)

The above figures excludes PLife REIT

Revenue - YTD Variance

RM'mil

YTD Dec 2015

Parkway Pantai

Parkway Pantai (Translation Difference)

Acibadem Holdings

Acibadem Holdings (Translation Difference)

IMU Health

Others

YTD Dec 2016

Check:

Check:

2,444.4

73.9

56.3

247.6

168.9

4.7

5.8

2,652.3

YTD Dec 2015 Parkway PantaiParkway Pantai(TranslationDifference)

AcibademHoldings

AcibademHoldings

(TranslationDifference)

IMU Health Others YTD Dec 2016

Parkway Pantai

Acibadem Holdings

IMU Health

Group (Excl PLife REIT)

Actual

@

Constant

Currency

8% 5%

9% 30%

8% 8%

9% 13%

YTD'17vs YTD'16

18

EBITDA: YoY EBITDA declined due to new hospitals

EBITDA (RM ‘mil) Variances

Margins

Margins

w/o New Hospitals & PLife REIT

w/o PLife REIT

385.7359.8 377.1 374.4

418.6

- - -(12.2) (16.3) (22.7)(41.5)

(84.2)

- - -

161.0

164.088.6

135.6

151.2

- - -

(4.4) (4.8)

1.4

(4.9)

- - -

23.226.8

19.5

16.0

27.4

- - -

(2.5)

(40.4)

20.9

(9.5)

(11.5)

- - -

65.065.0

67.8

89.0

69.0

- - -

617.0554.4

546.3

565.4

565.6

- - -

Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017

22.6% 20.1% 19.9% 18.3% 18.7% - - -

23.5% 21.1% 21.3% 20.2% 22.5% - - -

Segments

GROUP 0% -8% -8%

GROUP (Excl REIT) 4% -10% -10%

PLife REIT -23% 6% 6%

Others -22% NM NM

IMU Health 71% 18% 18%

Acibadem Holdings (New) NM -51% -51%

Acibadem Holdings (Existing) 12% -6% -6%

Parkway Pantai (New) -103% NM NM

Parkway Pantai (Existing) 12% 9% 9%

Q1'17

vs Q4'16

Q1'17

vs Q1'16

YTD'17

vs YTD'16

19

EBITDA Variance (RM’mil)

The above figures excludes PLife REIT

EBITDA: Actual Q1 EBITDA eroded by the depreciation of TL;

Mitigated by the appreciation of S$

EBITDA - YTD Variance

Check:

551.9

47.3

8.2

15.6

27.0

4.3

9.1

496.6

YTD Dec 2015 Parkway PantaiParkway Pantai(TranslationDifference)

AcibademHoldings

AcibademHoldings

(TranslationDifference)

IMU Health Others YTD Dec 2016

Parkway Pantai

Acibadem Holdings

IMU Health

IHH Group (Excl PLife REIT)

Actual

@

Constant

Currency

-10% -13%

-7% 10%

18% 18%

-10% -7%

YTD'17vs YTD'16

As at

31 Dec 2016

RM'mil

37,188

23,622

11,076

2,490

(13,295)

23,893

(1,907)

21,986

8,420

(7,487)

2,443

(5,044)

0.60

0.21

3.28

2.21

20

Healthy key coverage ratios

*: Based on last 12 months EBITDA

^: Excludes fixed deposits (>3 months) and amounts placed in money market funds of RM217.6 million (2016: RM209.2 million)

^^

Balance Sheet

As at

31 Mar 2017

RM'mil

Total Assets 37,904

- Tangible Assets 24,242

- Intangible Assets

Goodwill 11,204

Other intangibles 2,458

Total Liabilities (13,607)

Total Equity 24,297

Non-controlling Interests (1,832)

Total Shareholders' Equity (excluding non-controlling interests) 22,465

Net Tangible Assets ("NTA") (excluding non-controlling interests) (A) 8,803

Total Debt (B) (7,555)

Total Cash 2,774

Net Debt (C) (4,781)

Net Debt / NTA (C)/(A) 0.54

Net Debt / Equity 0.20

Gross Debt / EBITDA* (times) (B)/(D) 3.39

Net Debt / EBITDA* (times) (C)/(D) 2.14

21

Strong operating cash flows to support annual dividends and capital

expenditure for expansion

Cashflows @ 31 March 2017 (RM’mil)

2,423

433

31106

34 2,754

Cash @ 1/1/2017 Net cash fromOperating Activities

Net cash used inInvesting Activities

Net cash fromFinancing Activities

Effect of FX Cash @ 31/3/2017

Cash Reconciliation to Cashflow Statement: RM'mil

Cash per Balance Sheet 2,774

Less:

Bank overdrafts (12)

Cash collateral received (6)

Fixed deposits pledged (3)

Cash per Cashflow Statement 2,754

Cash

@ 31 Mar 2017 RM'mil

Parkway Pantai 1,419

Acibadem Holdings 90

IMU Health 194

Others 1,200

2,903

PLife REIT 89

2,992

(218)

2,774

Less:

Fixed Deposits placed for 3

months or more

Debt

@ 31 Mar 2017 RM'mil

Parkway Pantai 1,241

Acibadem Holdings 3,650

IMU Health -

Others 572

5,463

PLife REIT 2,092

7,555

RM' mil

Projected

Disbursements

Q2 2017 till 2018

Pantai Hospital Kuala Lumpur Expansion 162.1

Pantai Hospital Ayer Keroh Expansion 106.6

Pantai Hospital Klang Expansion 155.0

Gleneagles Medini Greenfield 162.8

Pantai Hospital Manjung Acquisition of Land 56.7

643.2

Gleneagles Hong Kong Hospital - 60% Greenfield 444.1

Gleneagles Shanghai Hospital - 70% Greenfield 643.7

Gleneagles Chengdu Hospital - 70% Brownfield 577.5

Gleneagles Nanjing Hospital - 60% Greenfield 91.9

1,313.1

Yangon Hospital - 52% Greenfield 282.2

Acibadem Maslak Expansion 332.8

Acibadem Altunizade Greenfield 16.6

Acibadem Atasehir Greenfield 98.9

Acibadem Kartal Greenfield 173.6

621.8

Total Unincurred Expansion Capital Expenditure 3,304.5

22

Expansion Capital Expenditure – Construction & Medical Equipment

*: Parkway will fund its share of the project cost

through its bank facility and the business partner

will fund their respective share. Amount shown is

total capex

Funded from Malaysia’s operating cash flows

and new bank facilities, if required

Funded from Acibadem’s operating cash flows

and bank facilities

*

*

*

*

Based on the following exchange rates:1 SGD : 3.16231TL : 1.22631 HKD : 0.57051 RMB : 0.642631 USD : 4.4304

*





23

Outlook & Prospects

24

Outlook & ProspectsOverall IHH Group

While 2017 is expected to be a challenging operating environment, we have a differentiated strategy in place to:

Consolidate and build on successeso Enhance service offerings at existing hospitals, ramp up new hospitals

o Prepare for progressive opening of new greenfield hospitals in 2018 & 2019

o Improve the mix on higher revenue intensity procedures

o Continually review and rebalance portfolio to optimise returns

Actively mitigate against cost pressures and geopolitical/forex risk

o Cost pressures: Tight cost controls and ramping up new facilities to maximise operational efficiencies

o Geopolitical and forex movements: Explore de-risking options for Acibadem’s currency exposure

We remain confident we can navigate macro uncertainties on our ability to leverage:

o Experienced management team with execution track record

o Strong brands and network of hospitals

o Robust balance sheet and operating cash flows

o 40-year track record of delivering superior clinical outcomes for patient





25

Appendix

26

Revenue: QoQ & YoY Comparison

Revenue1

Q1 2017 Q4 2016 Variance Q1 2017 Q1 2016 Variance YTD 2017 YTD 2016 Variance

RM'mil RM'mil % RM'mil RM'mil % RM'mil RM'mil %

Parkway Pantai:

- Singapore 961.5 892.1 8% 961.5 910.8 6% 961.5 910.8 6%

- Malaysia 416.8 392.2 6% 416.8 381.1 9% 416.8 381.1 9%

- Malaysia(New)

24.6 21.8 13% 24.6 10.2 140% 24.6 10.2 140%

- India 161.4 150.1 8% 161.4 127.8 26% 161.4 127.8 26%

- North Asia 65.2 68.6 -5% 65.2 67.3 -3% 65.2 67.3 -3%

- North Asia (New)

0.4 - - 0.4 - - 0.4 - -

- PPL Others* 44.2 46.4 -5% 44.2 46.8 -6% 44.2 46.8 -6%

Parkway Pantai 1,674.1 1,571.3 7% 1,674.1 1,543.9 8% 1,674.1 1,543.9 8%

Acibadem Holdings 887.8 945.6 -6% 887.8 819.0 8% 887.8 819.0 8%

Acibadem Holdings(New)

27.0 22.1 22% 27.0 17.0 59% 27.0 17.0 59%

Acibadem Holdings 914.8 967.6 -5% 914.8 836.0 9% 914.8 836.0 9%

IMU Health 62.9 58.0 9% 62.9 58.2 8% 62.9 58.2 8%

Others^ 0.5 0.6 -16% 0.5 6.3 -92% 0.5 6.3 -92%

GROUP (Excl REIT) 2,652.3 2,597.5 2% 2,652.3 2,444.4 9% 2,652.3 2,444.4 9%

PLife REIT Total 84.2 84.2 0% 84.2 79.7 6% 84.2 79.7 6%

Less: PLife REIT Inter-segment (51.7) (50.3) -3% (51.7) (48.8) -6% (51.7) (48.8) -6%

PLife REIT 32.5 34.0 -4% 32.5 30.9 5% 32.5 30.9 5%

GROUP 2,684.8 2,631.5 2% 2,684.8 2,475.4 8% 2,684.8 2,475.4 8%

Q-on-Q QTD Y-on-Y YTD Y-on-Y

1: Relates to external revenue only.

It excludes PLife REIT’s rental income earned from Parkway Pantai. Similarly, it excludes Parkway Pantai’s dividend and management fee income earned from PLife REIT.

*: PPL Others comprise mainly Parkway Pantai’s hospital in Brunei, corporate office as well as other investment holding entities within Parkway Pantai

^: Others comprise mainly IHH Group’s corporate office as well as other investment holding entities

27

EBITDA: QoQ & YoY Comparison

EBITDA1

Q1 2017 Q4 2016 Variance Q1 2017 Q1 2016 Variance YTD 2017 YTD 2016 Variance

RM'mil RM'mil % RM'mil RM'mil % RM'mil RM'mil %

Parkway Pantai:

- Singapore2

265.6 249.4 6% 265.6 243.0 9% 265.6 243.0 9%

- Malaysia 128.5 97.2 32% 128.5 113.0 14% 128.5 113.0 14%

- Malaysia(New)

0.4 (1.7) 126% 0.4 (6.4) 107% 0.4 (6.4) 107%

- India 2.1 14.0 -85% 2.1 (3.1) 167% 2.1 (3.1) 167%

- North Asia 10.6 10.8 -2% 10.6 16.6 -36% 10.6 16.6 -36%

- North Asia (New)

(84.5) (39.7) -113% (84.5) (5.8) NM (84.5) (5.8) NM

- PPL Others* 11.8 2.8 NM 11.8 16.2 -27% 11.8 16.2 -27%

Parkway Pantai 334.4 332.9 0% 334.4 373.5 -10% 334.4 373.5 -10%

Acibadem Holdings 151.2 135.6 12% 151.2 161.0 -6% 151.2 161.0 -6%

Acibadem Holdings(New)

(4.9) 1.4 NM (4.9) (3.2) -51% (4.9) (3.2) -51%

Acibadem Holdings 146.3 136.9 7% 146.3 157.8 -7% 146.3 157.8 -7%

IMU Health 27.4 16.0 71% 27.4 23.2 18% 27.4 23.2 18%

Others^ (11.5) (9.5) -22% (11.5) (2.5) NM (11.5) (2.5) NM

GROUP (Excl REIT) 496.6 476.4 4% 496.6 551.9 -10% 496.6 551.9 -10%

PLife REIT3

69.0 89.0 -23% 69.0 65.0 6% 69.0 65.0 6%

GROUP 565.6 565.4 0% 565.6 617.0 -8% 565.6 617.0 -8%

Q-on-Q QTD Y-on-Y YTD Y-on-Y

1: Relates to the EBITDA performance of each SBUs. After elimination of dividend income from within the Group

2: Includes rental expense incurred for lease of hospitals from PLife REIT

3: Includes rental income earned from lease of hospitals to Parkway Pantai

*: PPL Others comprise mainly Parkway Pantai’s hospital in Brunei, corporate office as well as other investment holding entities within Parkway Pantai

^: Others comprise mainly IHH Group’s corporate office as well as other investment holding entities





28

Questions & Answers

Documents

Results Briefing Presentation Q1 2017 2017... · 5 Q1 2017 Highlights Resilient core financial performance o Revenue increased 8% to RM2.7bil, o EBITDA decreased 8% to RM565.4mil